HIV regimen that typically consists of combination of 2 nucleoside and/or non-nucleoside reverse transcriptase inhibitors PLUS a protease inhibitor, reverse-transcriptase inhibitor, or integrase inhibitor
US DHHS first-line regimens
Emtricitabine/tenofovir (Truvada) + raltegravir
Emtricitabine/tenofovir + dolutegravir
Abacavir/lamivudine (Epzicom) + dolutegravir OR abacavir/lamivudine/dolutegravir (Triumeq)
Emtricitabine/tenofovir/elvitegravir/cobicistat (Stribild)
Emtricitabine/tenofovir + ritonavir + darunavir
WHO first-line regimen
Emtricitabine/tenofovir/efavirenz (Atripla)
Tenofovir + lamivudine + efavirenz
Emtricitabine/tenofovir (Truvada) + raltegravir
Emtricitabine/tenofovir + dolutegravir
Abacavir/lamivudine (Epzicom) + dolutegravir OR abacavir/lamivudine/dolutegravir (Triumeq)
Emtricitabine/tenofovir/elvitegravir/cobicistat (Stribild)
Emtricitabine/tenofovir + ritonavir + darunavir
Emtricitabine/tenofovir/efavirenz (Atripla)
Tenofovir + lamivudine + efavirenz
Antivirals
Antiarrhythmics
Anticoagulants
Antihistamines
Antipsychotics
Alpha blockers
Calcium channel blockers
Beta blockers